CSF Live

- Xenofon Baraliakos (Chair)
- Pedro Machado: Extra Muscular Manifestations in SpA
- Liane Gensler: Treatment Options for Extra Muscular Manifestations in SpA

- Maya Buch (Chair)
- Anja Strangfeld: Long term safety data and FDA labelling for JAKi in RA
- Chris Edwards: European PRAC review of JAKi data
- Lorenzo Dagna: Key considerations from a clinical perspective

- Iain McInnes- Chair
- Janet Pope - A Year in Review: RA
- Philip Mease - A Year in Review: PsA
- Xenofon Baraliakos - A Year in Review: AxSpA

- Rieke Alten (Chair)
- Eugen Feist (Treatment Considerations in RA Patients with Special Considerations: Cardiovascular and Renal Disease)
- Peter Taylor (Considerations When Treating Women of a Childbearing Age in Inflammatory Arthritis)

With the continued release of new treatment data in RA, axSpA, and PsA, this webinar will highlight the key data presented at ACR 2022. This session will review the latest safety and efficacy data of JAK inhibitors as well as the impact on clinical practice and patient outcomes. Join us and get your cytokine signalling updates from ACR 2022.
- Leonard Calabrese (Chair): RA: A Therapeutic Update
- Laura Coates: The Modern World of PsA Treatment
- Sofia Ramiro: The Latest Advances in axSpA

- Maya Buch (Chair)
- Anja Strangfeld: Latest understandings of JAKinib safety
- Chris Edwards: EULAR 2022 Recommendations update
- Lorenzo Dagna: Key considerations from a clinical perspective